Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ketamine does not decrease striatal dopamine D2 receptor binding in man.

Sargo Aalto1, Jussi Hirvonen, Jaana Kajander

  • 1Neuropsychiatric Imaging, Turku PET Centre, Turku University Central Hospital, Kiinamyllynkatu 4-8, 20520 Turku, Finland.

Psychopharmacology
|November 29, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of resilience in modifying the links between genetic propensity for mental disorders and irritability.

Journal of affective disorders·2026
Same author

Benzodiazepine Use and Mortality Risk: A Nationwide Cohort Study on New Benzodiazepine Users With a 5-Year Follow-Up.

Acta psychiatrica Scandinavica·2026
Same author

Progressive White Matter Changes in Mitochondrial Disease: A Quantitative MRI Study.

JIMD reports·2026
Same author

Use of multisensory information as facilitator of group schema therapy for borderline personality disorder.

BMC psychiatry·2026
Same author

The Brain Endocannabinoid System is Differentially Regulated in Male and Female Patients with First-Episode Psychosis.

Schizophrenia bulletin·2026
Same author

Connectivity-guided transcranial magnetic stimulation of the dopamine system: A proof-of-concept study.

Brain stimulation·2026

Ketamine, an NMDA receptor antagonist, did not alter striatal [(11)C]raclopride binding in healthy subjects. This suggests striatal dopamine release plays a minor role in ketamine-induced psychosis-like effects.

Area of Science:

  • Neuroscience
  • Psychopharmacology
  • Neuroimaging

Background:

  • Glutamate-dopamine interactions are implicated in psychosis induced by NMDA receptor antagonists like ketamine.
  • Previous in vivo human imaging studies on this interaction have yielded controversial results.

Purpose of the Study:

  • To investigate if ketamine, at high subanesthetic doses, reduces striatal [(11)C]raclopride binding potential in humans.
  • To determine if observed changes in striatal [(11)C]raclopride binding correlate with ketamine-induced behavioral effects.

Main Methods:

  • Utilized positron emission tomography (PET) with the [(11)C]raclopride displacement paradigm to assess striatal dopamine release.
  • Administered computer-driven subanesthetic ketamine infusions to healthy male subjects under controlled conditions.

Related Experiment Videos

  • Applied both region of interest-based and voxel-based analyses to PET imaging data.

    • Main Results:

    • The average plasma ketamine concentration achieved was 293+/-29 ng/ml.
    • Ketamine administration did not significantly alter striatal [(11)C]raclopride binding.
    • Ketamine induced behavioral effects, including hallucinations, but no correlation was found with [(11)C]raclopride binding displacement.

    Conclusions:

    • Ketamine does not decrease striatal [(11)C]raclopride binding in healthy individuals.
    • Striatal dopamine release appears to be of minor significance in mediating the psychosis-like effects of ketamine.